Literature DB >> 27429025

A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) Score.

Quirino Lai1, Daniele Nicolini, Milton Inostroza Nunez, Samuele Iesari, Pierre Goffette, Andrea Agostini, Andrea Giovagnoni, Marco Vivarelli, Jan Lerut.   

Abstract

OBJECTIVE: A novel and easy prognostic score based on the combination of pre-operatively available variables in patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) has been developed from a long waiting time (WT) training set and then validated in a short-WT set. SUMMARY OF BACKGROUND DATA: The role of radiological response to loco-regional therapies, alpha-fetoprotein modification, inflammatory markers, and length of WT has been recently shown to be important selection criteria for the risk of intention-to-treat (ITT)-death and recurrence.
METHODS: The training set consisted of 179 HCC patients listed for LT during the period January 2000 to December 2012 from the UCL Brussels Transplant Centre; the validation set consisted of 110 patients listed during the period January 2005 to December 2014 from the Ancona Liver Centre.
RESULTS: The proposed Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score was the best predictor of microvascular invasion. A TRAIN score ≥1.0 excellently stratified both the investigated populations in terms of ITT and recurrence survivals. When compared with Milan criteria, the proposed score allowed obtaining an increase of potentially transplantable patients (+8.9% in training set and 24.6% in validation set) without additive recurrence risks.
CONCLUSIONS: The proposed TRAIN score is an easy selection tool based on variables available before LT. This score enables the selection process to be refined in the 2 different scenarios of long and short WT. In case of longer WT, the score is better at predicting risk of death during the WT; in case of short WT, the score is better at identifying risk of post-LT recurrence.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27429025     DOI: 10.1097/SLA.0000000000001881

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  29 in total

Review 1.  Transplantation for hepatocellular cancer: pushing to the limits?

Authors:  Quirino Lai; Alessandro Vitale
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

2.  Liver Living Donation for Cancer Patients: Benefits, Risks, Justification.

Authors:  Silvio Nadalin; Lara Genedy; Alfred Königsrainer
Journal:  Recent Results Cancer Res       Date:  2021

3.  Twenty years after: from Milan criteria to a "blended" approach.

Authors:  Giovanni Battista Levi Sandri; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-21

4.  Resection or Transplant in Early Hepatocellular Carcinoma.

Authors:  Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch
Journal:  Dtsch Arztebl Int       Date:  2017-08-07       Impact factor: 5.594

Review 5.  The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution.

Authors:  Quirino Lai; Samuele Iesari; Fabio Melandro; Gianluca Mennini; Massimo Rossi; Jan Lerut
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-16

6.  Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Francis Y Yao
Journal:  Am J Transplant       Date:  2017-12-02       Impact factor: 8.086

Review 7.  Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation.

Authors:  Helena Degroote; Anja Geerts; Xavier Verhelst; Hans Van Vlierberghe
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

Review 8.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

Review 9.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

Review 10.  Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.

Authors:  Gonzalo Sapisochin; Jordi Bruix
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.